Synthesis and anti-hypertensive effects of the twin drug of Nicotinic Acid and Quercetin Tetramethyl Ether

17Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

Abstract

A novel twin drug consisting of nicotinic acid (VB3) and quercetin tetramethyl ether (QTME) has been synthesized as an antihypertensive in a total yield of 79.2% through methylation, hydrolysis, acylation and esterification starting from rutin. The structures of synthesized compounds were elucidated by 1H-NMR, 13C-NMR and elemental analysis. The anti-hypertensive effects of an oral daily dose (15 mg/kg) of the synthesized compounds in spontaneously hypertensive (SHR) rats and normotensive Wistar Kyoto (WKY) rats were analysed. The data demonstrate that the twin drug VB3-QTME both reduces the elevated blood pressure and prolongs the action time in SHR rats without effect on WKY rats. However, definitive evidence of a precise mechanism of action by which VB3-QTME might decrease blood pressure remains elusive. Based on the results, the therapeutic potential of this twin drug is discussed. © 2014 by the authors; licensee MDPI, Basel, Switzerland.

Cite

CITATION STYLE

APA

Wang, Z., Yang, L., Cui, S., Liang, Y., & Zhang, X. (2014). Synthesis and anti-hypertensive effects of the twin drug of Nicotinic Acid and Quercetin Tetramethyl Ether. Molecules, 19(4), 4791–4801. https://doi.org/10.3390/molecules19044791

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free